Phosphorylation of IRS4 by CK1 γ 2 promotes its degradation by CHIP through the ubiquitin/lysosome pathway
Conclusions: IRS4, as a new substrate of CHIP, is negatively regulated by CK1γ2 at the posttranslational level, and specific CK1γ2 agonists may be a potentially effective strategy for treating patients with osteosarcoma.
Source: Theranostics - Category: Molecular Biology Authors: Xinchun Li, Li Zhong, Zhuo Wang, Huiming Chen, Dan Liao, Ruhua Zhang, Hongyu Zhang, Tiebang Kang Tags: Research Paper Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Insulin | Osteosarcoma | PET Scan | Students | Universities & Medical Training